Radiation boost may help CAR-T cells wipe out stubborn lymphoma

NCT ID NCT05514327

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a special type of radiotherapy (ultra-fraction) before CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 20 adults who have failed at least two prior treatments will receive the radiotherapy followed by CAR-T cells. The main goal is to see how many patients respond at 3 months, with longer-term follow-up for progression and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ultra-fraction radiotherapy and CD19 CAR-T cell therapy
What this could lead to
If it works, this could improve how well CAR-T therapy controls lymphoma in patients who have run out of other options.
What could go wrong
This is a very small, early study with only 20 participants, so results may not apply widely. The combination could also cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRIDGING THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.